Membranous glomerulonephritis
Drug research and approvals for membranous glomerulonephritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 47 studies of membranous glomerulonephritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 47
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous NephropathyNCT07861204 · Phase 2 / Phase 3 · Peking University First Hospital · starts Jan 21, 2026
- A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyNCT07851220 · Phase 3 · Amgen · starts Oct 1, 2026
- A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseNCT07571746 · Phase 2 · AstraZeneca · starts Mar 28, 2026
- SLIT ABS: Study on Patients With Autoimmune PodocytopathyNCT07516964 · Not applicable · Meyer Children's Hospital IRCCS · starts Jun 10, 2025
- Rivaroxaban in Idiopathic Membranous NephropathyNCT07404436 · Phase 4 · Beijing Friendship Hospital · starts Jan 5, 2024
- Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and…NCT07289763 · Phase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd · starts Dec 31, 2025
- Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous…NCT07266181 · Phase 1 · The First Affiliated Hospital of Air Force Medical University · starts Dec 8, 2025
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy…NCT07204275 · Phase 2 / Phase 3 · Vertex Pharmaceuticals Incorporated · starts Sep 30, 2025
Phase 3 7
- RituximabB-lymphocyte antigen CD20 binding agent
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- CyclosporineCyclophilin A modulator
- CyclophosphamideDNA inhibitor
- PrednisoneGlucocorticoid receptor agonist
- ChlorambucilDNA inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
Phase 2 3
- BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor
- IptacopanComplement factor B inhibitor
- CosyntropinMelanocortin receptor 2 agonist
Phase 1 or earlier 2
- CorticotropinMelanocortin receptor 2 agonist
- FelzartamabLymphocyte differentiation antigen CD38 inhibitor
How its trials ended
112 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 38% met their primary endpoint, 6% missed it and 56% stopped early.
- Ongoing4742%
- Completed, result not reported2825%
- Status unknown2119%
- Met its primary endpoint65%
- Stopped: other or unclear44%
- Stopped: sponsor or business decision33%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA